department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Upneeq · pharmadog

pharmadog
drugs
Upneeq

drug

patient view →

oxymetazoline hydrochloride

Marketedupdated 2mo ago

by RVL Pharmaceuticals Inc

Approved

community read0 votes

all catalysts(1)

phase 2 initiation · 1

phase 2 initiation

Beijing Chao-Yang Hospital — oxymetazoline hydrochloride (Phase II Trial Initiation)

oxymetazoline hydrochloride

News(0)

no news has mentioned this drug yet

brand

Upneeq

generic

oxymetazoline hydrochloride

indication

Ptosis

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed 50m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

May 2, 2028

~1.8 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (19)

Dec 16, 2039method-of-use (U-2849)US 10799481
Dec 16, 2039formulationUS 10814001
Dec 16, 2039formulationUS 10898573
Dec 16, 2039method-of-use (U-2849)US 10940138
Dec 16, 2039formulationUS 11103482
Dec 16, 2039formulationUS 11311515
Dec 16, 2039method-of-use (U-2849)US 11324722
Dec 16, 2039formulationUS 11541036
Dec 16, 2039method-of-use (U-2849)US 11701343
Jun 11, 2035method-of-use (U-2567)US 10335391
Jun 11, 2035method-of-use (U-2921)US 10751325
Jun 11, 2035method-of-use (U-3494)US 11517560
Jun 11, 2035method-of-use (U-3494)US 12350255
Jun 11, 2035method-of-use (U-2306)US 9974773
Dec 1, 2031formulationUS 8883838
Aug 26, 2031method-of-use (U-2849)US 10912765
Aug 26, 2031method-of-use (U-2849)US 8357714
Aug 26, 2031method-of-use (U-2849)US 9867808
May 2, 2028method-of-use (U-1959)US 78120491.8y

🐶 often sniffed alongside

top 3

drugoxymetazoline1 co-mentions · 1 sources
companyBeijing Chao-Yang Hospital1 co-mentions · 1 sources
tagOphthalmology1 co-mentions · 1 sources

Trials studying oxymetazoline hydrochloride

phase3LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis.recruitingn=234